MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials-Reference-Cited by-同舟云学术

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Published:2018-12-04 Issue:6 Volume:25 Page:1809-1816
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Hegi Monika E.,Genbrugge Els,Gorlia Thierry,Stupp Roger,Gilbert Mark R.,Chinot Olivier L.^ORCID,Nabors L. Burt^ORCID,Jones Greg^ORCID,Van Criekinge Wim,Straub Josef,Weller Michael

Funder

Clinical Trial Groups

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROBIN: A unified nanopore-based sequencing assay integrating real-time, intraoperative methylome classification and next-day comprehensive molecular brain tumour profiling for ultra-rapid tumour diagnostics;2024-09-11

2. Temozolomide Use in Elderly Patients with MGMT Promoter Unmethylated Glioblastoma: Is It Finally Time to Dismount a Dead Horse?;Neuro-Oncology;2024-07-31

3. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients;Neuro-Oncology;2024-07-03

4. Sphingolipid Signaling and Complement Activation in Glioblastoma: A Promising Avenue for Therapeutic Intervention;BioChem;2024-06-06

5. Small-molecule Molephantin induces apoptosis and mitophagy flux blockage through ROS production in glioblastoma;Cancer Letters;2024-06